Literature DB >> 2449160

Prostacyclin and iloprost: equal efficiency in preserving high energy phosphates in the dog heart following coronary artery ligation.

M Pissarek1, H Goos, J Nöhring, J Graff, G Buller, I Beyerdörfer, H J Mest, K F Lindenau, E G Krause.   

Abstract

The influence of PGI2 and iloprost on the contents of high energy phosphates, cAMP, glycolytic metabolites and on cardiac performance was investigated in open-chest dogs subjected to 3 h of ischaemia, induced by occlusion of the left anterior descending coronary artery. The administration of drugs for 2 h, starting 1 h after the onset of ischaemia, resulted in a normalization and an appreciable reduction in the loss of high energy phosphates in the non-ischaemic and ischaemic left ventricular muscle, respectively, leading to an improvement in the phosphate potential of the cardiac tissue. A reduction in the ischemia-induced rise in cAMP levels was observed, indicating a lower catecholamine overflow in the presence of these drugs. PGI2 and iloprost in the dose employed significantly decreased cardiac preload, which was found to be elevated in the untreated animals after coronary artery ligation. The observed effect of PGI2 and its mimetic on the haemodynamics, as well as on myocardial cAMP and high energy phosphate levels of the heart, may be considered helpful in the phase of temporary imbalance between energy demand and supply during acute ischaemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449160     DOI: 10.1007/bf01907227

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  35 in total

1.  Cyclic AMP levels in ischaemic and non-ischaemic myocardium following coronary artery ligation: relation to ventricular fibrillation.

Authors:  T Podzuweit; A J Dalby; G W Cherry; L H Opie
Journal:  J Mol Cell Cardiol       Date:  1978-01       Impact factor: 5.000

2.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia.

Authors:  A M Lefer; M L Ogletree; J B Smith; M J Silver; K C Nicolaou; W E Barnette; G P Gasic
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

3.  Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic iloprost (ZK 36 374) in acute myocardial ischemia.

Authors:  C Thiemermann; E Steinhagen-Thiessen; K Schrör
Journal:  J Cardiovasc Pharmacol       Date:  1984 Mar-Apr       Impact factor: 3.105

4.  Effect of prostacyclin on the severity of ischaemic injury in rabbit hearts subjected to coronary ligation.

Authors:  A Edlund; K Sahlin; A Wennmalm
Journal:  J Mol Cell Cardiol       Date:  1986-10       Impact factor: 5.000

5.  Sustained protection by iloprost of the porcine heart in the acute and chronic phases of myocardial infarction.

Authors:  C D de Langen; W H van Gilst; H Wesseling
Journal:  J Cardiovasc Pharmacol       Date:  1985 Sep-Oct       Impact factor: 3.105

6.  Prostaglandins and myocardial noradrenaline overflow after sympathetic nerve stimulation during ischemia and reperfusion.

Authors:  K Schrör; K Funke
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

7.  Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models.

Authors:  K A Reimer; R B Jennings; F R Cobb; R H Murdock; J C Greenfield; L C Becker; B H Bulkley; G M Hutchins; R P Schwartz; K R Bailey
Journal:  Circ Res       Date:  1985-05       Impact factor: 17.367

8.  PGI2 prevents ischemia-induced alterations in cardiac catecholamines without influencing nerve-stimulation-induced catecholamine release in nonischemic conditions.

Authors:  K Schrör; H Darius; K Addicks; R Köster; E F Smith
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

9.  Effect of prostacyclin on vascular capacity in the dog.

Authors:  T G Fulghum; J P DiMarco; E W Supple; I Nash; J Gendlerman; D F Eton; J B Newell; R M Zusman; W J Powell
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

10.  Improved protection in myocardial ischemia by combined prostacyclin administration and intraaortic balloon pumping.

Authors:  H Goos; E G Krause; I Beyerdörfer; K F Lindenau; J Nöhring; J Schimke; C Wagenknecht; R A Parsi
Journal:  Biomed Biochim Acta       Date:  1984
View more
  3 in total

1.  Beneficial effect of beraprost, a prostacyclin-mimetic agent, on post-hypoxic recovery of cardiac function and metabolism in rabbit isolated hearts.

Authors:  K Tanonaka; Y Maruyama; S Takeo
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 2.  Significance of myocardial eicosanoid production.

Authors:  M van Bilsen; W Engels; G J van der Vusse; R S Reneman
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

3.  Cardioprotective potency of the radical scavenger S-2-(3 aminopropylamino) ethylphosphorothioic acid in the post-ischaemic rat heart.

Authors:  M Pissarek; F Jänichen; I E Blasig; R Haseloff; T Keller; E Tapp; E G Krause
Journal:  Mol Cell Biochem       Date:  1995-04-26       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.